Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
The potential use of artificial intelligence for venous thromboembolism prophylaxis and management: clinician and healthcare informatician perspectives
7
Zitationen
14
Autoren
2024
Jahr
Abstract
Venous thromboembolism (VTE) is the leading cause of preventable death in hospitalized patients. Artificial intelligence (AI) and machine learning (ML) can support guidelines recommending an individualized approach to risk assessment and prophylaxis. We conducted electronic surveys asking clinician and healthcare informaticians about their perspectives on AI/ML for VTE prevention and management. Of 101 respondents to the informatician survey, most were 40 years or older, male, clinicians and data scientists, and had performed research on AI/ML. Of the 607 US-based respondents to the clinician survey, most were 40 years or younger, female, physicians, and had never used AI to inform clinical practice. Most informaticians agreed that AI/ML can be used to manage VTE (56.0%). Over one-third were concerned that clinicians would not use the technology (38.9%), but the majority of clinicians believed that AI/ML probably or definitely can help with VTE prevention (70.1%). The most common concern in both groups was a perceived lack of transparency (informaticians 54.4%; clinicians 25.4%). These two surveys revealed that key stakeholders are interested in AI/ML for VTE prevention and management, and identified potential barriers to address prior to implementation.
Ähnliche Arbeiten
Correspondence - Tranexamic acid for traumatic brain injury
2005 · 11.688 Zit.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 · 9.309 Zit.
Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials
2016 · 7.352 Zit.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
2002 · 6.931 Zit.
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 · 6.694 Zit.
Autoren
Institutionen
- Beth Israel Deaconess Medical Center(US)
- Harvard University(US)
- National Blood Clot Alliance(US)
- Weber State University(US)
- Massachusetts General Hospital(US)
- Centers for Disease Control and Prevention(US)
- National Center on Birth Defects and Developmental Disabilities(US)
- Cancer Research Institute(US)
- Memorial Sloan Kettering Cancer Center(US)